On Effective and Efficient Experimental Designs for Neurobehavioral Screening Tests: The Choice of a Testing Time for Estimating the Time of Peak Effects by Toyinbo, Peter A
University of South Florida
Scholar Commons
Graduate Theses and Dissertations Graduate School
7-6-2004
On Effective and Efficient Experimental Designs
for Neurobehavioral Screening Tests: The Choice
of a Testing Time for Estimating the Time of Peak
Effects
Peter A. Toyinbo
University of South Florida
Follow this and additional works at: https://scholarcommons.usf.edu/etd
Part of the American Studies Commons
This Thesis is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate
Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact scholarcommons@usf.edu.
Scholar Commons Citation
Toyinbo, Peter A., "On Effective and Efficient Experimental Designs for Neurobehavioral Screening Tests: The Choice of a Testing
Time for Estimating the Time of Peak Effects" (2004). Graduate Theses and Dissertations.
https://scholarcommons.usf.edu/etd/1273
  
 
On Effective and Efficient Experimental Designs for Neurobehavioral Screening Tests:  
 
The Choice of a Testing Time for Estimating the Time of Peak Effects 
 
 
 
 by 
 
 
 
Peter A. Toyinbo 
 
 
 
 
 
A thesis submitted in partial fulfillment 
of the requirements for the degree of 
Master of Science in Public Health 
Department of Epidemiology and Biostatistics 
College of Public Health 
University of South Florida  
 
 
 
Major Professor:  Yiliang Zhu, Ph.D. 
Member:  C. Hendricks Brown, Ph.D. 
Member:  Getachew Dagne, Ph.D. 
 
 
Date of Approval: 
July 06, 2004 
 
 
 
Keywords:  Neurotoxicity, dose response, modeling, methodology, benchmark dose. 
 
 
© Copyright 2004, Peter A. Toyinbo 
  
 
 
 
 
 
 
 
 
 
 
DEDICATION 
To Grace 
For as long as we can remember, each step of our remarkable journey, you continue to be 
an inspiration to us. You freely bestow to our family all that you have, all that you are. 
Gracefully, you led us to one conviction: we are blessed with a lasting amazing Grace. 
We love you, Grace. 
Peter, for Funbi, Femi and Tomi. 
  
 
 
ACKNOWLEDGMENTS 
 I am grateful to Dr. Yiliang Zhu, my advisor and major professor, for his 
encouragement, support, research expertise, critical evaluation and excellent guidance in 
grooming this thesis into its end product. In addition, the gracious time, technical 
guidance and professional advice that Dr. Wei Wang gave were invaluable to the contents 
of this thesis. 
 I gratefully acknowledge Dr. Hendricks Brown and Dr. Getachew Dagne for their 
participation on this thesis committee and for sharing key insights and valued expertise in 
the completion of the thesis. 
  A special thank to my friends and colleagues in the Health Risk 
Assessment Methodology Group of the University of South Florida College of Public 
Health: Michael Wessel, Jenny Jia and Dr. Sanjay Muniredi for all the hours of brain 
storming, thoughtful comments, and relaxing fun that went into this thesis. 
  I wish to acknowledge and thank Dr. Virginia Moser of US EPA as the 
provider of the FOB data used to carry out this thesis. 
 Finally, as a fruitful tree would acknowledge its root for its nurture, I am 
incredibly indebted to my family for their support, patience, understanding, and for 
believing in me. Especially to Grace, my wife, this accomplishment is the resultant of 
your countless gentle nudges. 
 i 
 
 
 
 
 
TABLE OF CONTENTS 
 
LIST OF TABLES  iii 
 
LIST OF FIGURES  iv 
 
ABSTRACT   vi 
 
INTRODUCTION 1 
 Neurotoxicity and Neurobehavioral Screening Methods 1 
 Neurobehavioral Screening Protocol 3 
 Experiment Based TOPE Estimate 4 
 Model Based TOPE Estimate 5 
 Objectives of this Study  6 
 
THEORY AND METHODS 8  
 Dose-Time-Response Models 8 
 TOPE Estimation 9 
 Testing Times and Dose-Time-Response Profiles 10 
 Consideration for Optimal Design Theory 11 
  General Principles 11 
  Optimal Design under Nonlinear Model 13 
 Simulation Rational 17 
 Experimental Designs 18 
 Simulation Steps 20 
  Step 1: Define the Dose-Response Model and Population Parameters 20 
  Step 2: Generate Datasets for Each Design 22 
  Step 3: Estimate Parameters 23 
  Case Large Variance 23 
 Simulation under Two Additional Models 24 
Toxico-Diffusion Model: Acute DDT Experiment / Neuromuscular 
Domain 24 
Rational Function Model: Acute TET Experiment / Activity Domain 24 
 
RESULTS   28 
 Acute TET Experiment: Activity Domain / Linear-Exponential Model 28 
Distribution of TOPE Estimates 28 
  Distribution of TOPE Estimates: Large Variance 32 
 Acute DDT experiment: Neuromuscular Domain/ Toxico-Diffusion Model 37 
  
 
 ii 
 Acute TET Experiment/ Activity Domain:  Rational Function Model 41 
  Rational Function Model: Case One 43 
  Rational Function Model: Case Two 46 
 Summary of Results and Interpretations 50 
 
DISCUSSION   54 
 
REFERENCES  59 
 
 
 iii 
 
 
 
 
 
LIST OF TABLES 
 
Table 2.1 Testing Times for EPA/IPCS Collaborative Study Design and  
 Candidate Designs    19 
 
Table 2.2 Table of Four Testing Times1 (Hours) by 30 Different Designs 20 
 
Table 2.3 Acute TET Exposure Study: Activity Scores with Linear Exponential 
Model Fit    21 
 
Table 2.4 Toxico-diffusion Model fit to Neuromuscular Scores of Rats Exposed  
 to DDT 25 
 
Table 2.5 Rational Function Model Specifications        26 
 
Table 3.1 Convergence across Designs for Acute TET Experiment: Simulated 
Activity Scores (Large Variance) with Linear-Exponential Model Fit 33 
 
Table 3.2 Table of Designs with Unique 2nd Testing Times for Acute DDT 
Experiment         38 
 
Table 3.3 Summary of Designs for the Estimation of TOPE    51  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
 
 
 
 
LIST OF FIGURES 
 
Figure 2.1 Theoretical Response-Time Profiles for the Highest Dose Group  
 Based on Comparison Models: Activity Scores of Rats Exposed to  
 TET 27 
 
Figure 3.1 Boxplots of TOPE Estimates across Designs for Acute TET  
 Experiment: Simulated Activity Scores with Linear Exponential  
 Model Fit    29 
 
Figure 3.2 Bias and Relative Bias of TOPE Estimates across Designs for Acute  
 TET Experiment: Simulated Activity Scores with Linear Exponential 
Model Fit   30 
 
Figure 3.3 Median TOPE Estimates across Designs for Acute TET Experiment: 
Simulated Activity Scores with Linear Exponential Model Fit   31 
 
Figure 3.4 Plots of Coefficient of Variation (CV) across Designs for Acute TET 
Experiment: Simulated Activity Scores with Linear Exponential  
 Model Fit   32 
 
Figure 3.5 Median TOPE Estimates across Designs for Acute TET Experiment: 
Simulated Activity Scores (Large Variance) with Linear Exponential 
Model Fit   34 
 
Figure 3.6 Bias and Relative Bias of TOPE Estimates across Designs for Acute  
 TET Experiment: Simulated Activity Scores (Large Variance) with  
 Linear Exponential Model Fit   35 
 
Figure 3.7 Boxplots of TOPE Estimates across Designs for Acute TET  
   Experiment: Simulated Activity Scores (Large Variance) with Linear 
Exponential Model Fit       36 
 
Figure 3.8 Coefficient of Variation (CV) Across Designs for Acute TET  
 Experiment: Simulated Activity Scores (Large Variance) with Linear 
Exponential Model Fit   37 
 
Figure 3.9 Median TOPE Estimates across Designs for Acute DDT Experiment: 
Simulated Neuromuscular Scores3 with Toxico-Diffusion Model Fit   39 
 
 v 
Figure 3.10 Relative Bias of TOPE Estimates across Designs for Acute DDT 
Experiment: Simulated Neuromuscular Scores3 with Toxico-Diffusion 
Model Fit   39 
 
Figure 3.11 Boxplots of TOPE Estimates across Designs for Acute DDT  
 Experiment: Simulated Neuromuscular Scores3 with Toxico-Diffusion 
Model Fit   40 
 
Figure 3.12 Plots of Coefficient of Variation (CV) across Designs for Acute DDT 
Experiment: Simulated Neuromuscular Scores3 with Toxico-Diffusion 
Model Fit   41 
 
Figure 3.13 Convergences across Designs of Acute TET Experiment: Simulated 
Activity Scores with Rational Function Model Fit   42 
 
Figure 3.14 Boxplots of TOPE Estimates across Designs of Acute TET  
 Experiment: Simulated Activity Scores (TOPE = 6.16 hr) with  
 Rational Function Model Fit   43 
 
Figure 3.15 Median TOPE Estimates across Designs of Acute TET Experiment: 
Simulated Activity Scores (TOPE = 6.16 hr) with Rational Function 
Model Fit   44 
 
Figure 3.16 Relative Bias of TOPE Estimates across Designs of Acute TET 
Experiment: Simulated Activity Scores (TOPE = 6.16 hr) with  
 Rational Function Model Fit   45 
 
Figure 3.17 Plots of Coefficient of Variation (CV) across Designs of Acute TET 
Experiment: Simulated Activity Scores (TOPE = 6.16 hr) with  
 Rational Function Model Fit   46 
 
Figure 3.18 Boxplots of TOPE Estimates across Designs of Acute TET  
 Experiment: Simulated Activity Scores (TOPE = 2 hr) with Rational 
Function Model Fit   47 
 
Figure 3.19 Median and Relative Bias of TOPE Estimates across Designs of Acute 
TET Experiment: Simulated Activity Scores (TOPE = 2 hr) with  
 Rational Function Model Fit   48 
 
Figure 3.20 Plots of Coefficient of Variation (CV) across Designs of Acute TET 
Experiment: Simulated Activity Scores (TOPE = 2 hr) with Rational 
Function Model Fit   49 
 
 vi 
 
 
 
 
 
ON EFFECTIVE AND EFFICIENT EXPERIMENTAL DESIGNS FOR 
NEUROBEHAVIORAL SCREENING TESTS: THE CHOICE OF A TESTING TIME 
FOR ESTIMATING THE TIME OF PEAK EFFECTS 
 
Peter A. Toyinbo 
 
ABSTRACT 
In its latest neurotoxicity guidelines released by the US EPA Office of Prevention, 
Pesticides and Toxic Substances (OPPTS) in 1998, it is recommended that in a 
neurobehavioral testing, at a minimum, for acute studies, observations and activity testing 
should be made before the initiation of exposure, at the estimated TOPE (time of peak 
effects) within 8 hrs of dosing, and at 7 and 14 days after dosing. It is recommended that 
estimation of TOPE be made by dosing pairs of rats across a range of doses and making 
regular observations of gait and arousal. However it is well known that TOPE may vary 
with end points or exposure conditions. 
In order to derive quantitative safety measures such as the benchmark doses 
(BMD), dose-time-response modeling must be done first and a model-based estimate is 
then implied. In many cases, the overall BMD corresponds to a TOPE estimate. In such 
cases a substantial variation in the TOPE estimate in turn may result in substantial 
variation in BMD estimate. Therefore a reliable statistical estimate of TOPE is crucial to 
the correct determination of BMD.  
 We therefore performed simulation studies to assess the impact of the experiment-
based TOPE on the statistical estimation of the true TOPE on the basis of a fitted dose-
 vii 
time-response model. The simulation allows for the determination of the optimal timing 
range for the 2nd testing. 
The results indicated that given only four repeated observations, the optimal 
second testing time was at about midway between time zero and the true TOPE. 
Choosing the second testing time at the TOPE may not generate statistical estimates 
closer to the true TOPE. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Neurotoxicity and Neurobehavioral Screening Methods 
Chemicals are an integral part of life, with the capacity to improve as well as 
endanger health. A link between human exposure to some chemical substances and 
neurotoxicity has been firmly established (Anger, 1986; US EPA, 1990). Neurotoxicity is 
defined as adverse effects on either the structure or functions of the nervous system (US 
EPA, 1998a). In addition to its primary role in psychological functions, the nervous 
system controls most, if not all, other bodily processes. Nervous system is sensitive to 
perturbation from various sources and has limited ability to regenerate. Therefore, there is 
a need for regulation of neurotoxicants on a scientific basis. It is important to have 
consistent guidance on how to evaluate neurotoxic substances and assess their potential to 
cause transient or persistent, direct or indirect effects on human health. (US EPA, 1998a) 
In the EPA’s neurotoxicity risk assessment guidelines (US EPA, 1998a), five 
categories of endpoints were described: structural or neuropathological, 
neurophysiological, neurochemical, behavioral, and developmental. The guidelines 
outline the scientific basis for evaluating effects due to exposure to neurotoxicants and 
discuss principles and methods for evaluating data from human and animal studies using 
the described endpoints. 
 In collaboration with international organizations such as the International 
Programme on Chemical Safety (IPCS), the US EPA has been developing and evaluating 
test methods that may eventually lead to an integrated approach to risk assessment of 
neurotoxicity. The EPA recommended the use of neurobehavioral screening methods as a 
first tier test for identifying and quantifying neurotoxicity of chemicals from animal 
studies (MacPhail et al, 1997; US EPA, 1998a). One such neurotoxicity screening battery 
is the Functional Observation Battery (FOB) in conjunction with motor activity (US 
EPA, 1998b). For the purpose of this thesis, FOB will be construed to encompass 
neurobehavioral screening methods.  
 
1.2 Time of Peak Effects and Benchmark Dose Estimation  
 There have been increasing efforts to improving the scientific methodologies for 
risk assessment of neurotoxic effects in human due to chemical exposure. US EPA has 
recommended to use BMD as an alternative to the NOAEL/LOAEL methodology (US 
EPA, 1998a). The benchmark dose (BMD) approach aims to identify an effective dose 
(ED) that would induce an increase (typically 1-10%) of the attributable risk of adverse 
effects over background through empirical modeling (Crump, 1984; Zhu 2001). This 
approach provides for more quantitative dose-response evaluation when sufficient data 
are available and it takes into account the variability in the data and the slope of the dose-
response curve. (Crump, 1984; U.S. EPA, 1995; Zhu, 2001).  
A number of non-linear mixed effects models have been developed for describing 
the dose-time-response relationships observed in the FOB data from the EPA Superfund 
study and the IPCS Collaborative study (Zhu, 2001; Zhu et al, 2003a,b). Methods to 
2 
 3 
implement benchmark dose methodology for neurotoxicity data have also been developed 
(Zhu et al, 2003c). Zhu (2003) showed that both estimates of attributable risk and BMD 
vary with exposure level, time of testing, and spontaneous risk. He argues that a time 
profile of BMD be considered and the smallest value over the time course be reported as 
the overall value for deriving a safety dose in regulation. For some dose-response models 
(that will be focus of this thesis), this overall BMD must correspond to the time of peak 
effects (TOPE). A reliable estimate of TOPE is therefore crucial to the correct 
determination of BMD.  
 
1.3 Neurobehavioral Screening Protocol 
Neurotoxicity testing procedures must meet certain data requirements of the U.S. 
EPA under the Toxic Substances Control Act and the Federal Insecticide, Fungicide and 
Rodenticide Act (US EPA, 1991). In order to minimize variations among the testing 
procedures, the US EPA Office of Prevention, Pesticides and Toxic Substances (OPPTS) 
harmonized several other guidelines into a single set of OPPTS guidelines released in 
1998 (US EPA, 1998b). Specifically for single dose experiments, the OPPTS guidelines 
include the following recommendation for time of testing: “At a minimum, for acute 
studies, observations and activity testing should be made before the initiation of 
exposure, at the estimated TOPE (time of peak effects) within 8 hrs of dosing, at 7 and 14 
days after dosing. Estimation of TOPE may be made by dosing pairs of rats across a 
range of doses and making regular observations of gait and arousal.” 
 The OPPTS guidelines of 1998 (US EPA, 1998b) was preceded by a similar 
design protocol that was adopted in the IPCS Collaborative study (Moser et al, 1997a,b) 
 4 
and which produced the FOB data used in this thesis. Under the Collaborative study 
protocol, for the acute exposure experiments, FOB and motor activity measurements 
were conducted at four testing times:  
t1  immediately prior to exposure,  
t2  estimated time of peak effect (TOPE), 
t3  one day after dosing, and  
t4 seven days after dosing.  
 
1.4 Experiment Based TOPE Estimate 
 The endpoints of FOB tests consist of about 30 non-invasive measures of gross 
functional deficits that quantify neurobehavioral changes in animals exposed to a 
chemical substance. The FOB measures can be grouped into six neurobehavioral 
functional domains, including activity, neuromuscular, excitability, sensorimotor, 
physiological and autonomic functions (McDaniel and Moser, 1993; Moser et al, 1997a). 
Whereas individual endpoints can be used for risk assessment, there are efforts to 
explore the use of composite domain scores. Obviously it is practically inefficient to 
employ all available endpoints in a pilot study. Alternatively, the US EPA recommended 
that the method for selecting time of testing to be used in acute studies be based on range-
finding pilot study using gait and arousal as the endpoints for determining TOPE (Moser 
et al, 1997a; US EPA, 1998b), thus reducing the number of endpoints to a more 
manageable size of two. As a result, the experimentally determined TOPE is by design 
unique to individual chemical agents. However a previous study has shown that when the 
recommended end-points for determining the TOPE in a pilot study are limited to only 
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gait and arousal, the second testing time (t2) selected (assuming four testing times) for the 
acute study proper based on this TOPE estimate may not be appropriate for other 
neurotoxic effects or endpoints which show a different time course (Lammers and Kulig, 
1997). Conceivably, apart from random error of measurement, the TOPE estimate thus 
obtained might systematically differ from the true TOPE (parameter). For this reason, the 
timing adopted for the second testing may differ from the true TOPE substantially even 
following the EPA guidelines. The impact of such selection is largely unknown.  
 
1.5 Model Based TOPE Estimate 
The FOB measures were multi-scale and also were grouped into six functional 
domains. In order to reduce the number of endpoints for statistical efficiency, these multi-
scale measures were converted to domain-specific composite scores (McDaniel and 
Moser, 1993; Zhu et al, 2003b). Typically, a composite score would be a weighted 
average of individual scores involved. According to Zhu et al (2003b) this approach 
mandates, as a prerequisite, conversion of individual measures to a common ordinal 
scale. The authors therefore converted every measure, continuous or categorical, into a 4-
level ordinal scale in which ranking of an observation was based on the extent to which 
the corresponding neurobehavioral response was “common” in occurrence in a reference 
group.  
Zhu et al (2003b) then proceeded to dose-time-response modeling of the domain-
specific composite scores, i.e. of grouped FOB measures, as part of the steps leading to 
BMD estimation. For each acute experiment (or chemical), a statistical model was fitted 
separately to each of six domains to produce a total of six domain-specific TOPE 
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estimates. It was these model-based TOPE estimates that were used to compute the 
benchmark dose for each composite score.  
Expectedly, for individual chemicals, each of the six domain-specific model-
based TOPE estimates might be different than the single experiment-based TOPE 
estimate used from the pilot study. While differences in values between these two types 
of TOPE estimates are expected, the reliability of model-based TOPE estimates cannot be 
presumed. It is conceivable that the reliability of the model-based TOPE estimates might 
also be affected by the uncertainty inherent in the timing of the 2nd testing that was 
determined from experiment-based TOPE estimate.  
 
1.6 Objectives of this Study 
We believe that any uncertainty about the TOPE derived from the pilot 
experiment is carried over to variability in the timing of the 2nd testing. Furthermore, it is 
not clear how variability in the 2nd testing time around the true TOPE could impact the 
statistical estimation of the true TOPE on the basis of a fitted dose-time-response model. 
Clearly there is a need for effective experimental designs to facilitate the estimation of 
the true underlying TOPE by any well fitted model.  On the contrary, a poorly designed 
experiment often results not only in inefficient use of time and other resources, but also in 
invalid (bias) and/or imprecise (large variation) estimation. Therefore investigating 
effective and efficient time points in FOB tests for identifying TOPE may lead to 
improved neurotoxicity screening procedures. It is this aspect of the neurobehavioral 
screening protocol for acute experiments that this thesis will focus on.  
The main research questions this thesis seeks to answer are as follows: 
 7 
1. Under the proposed protocol of the US EPA/IPCS Collaborative study, what 
impacts would the timing of the 2nd testing have on estimating the true TOPE? 
2. If we fix the 1st, 3rd and 4th FOB testing times, what would be the optimal range 
for the 2nd testing time to effectively estimate the TOPE?  
3. How sensitive are the non-linear mixed effects models under consideration to 
variability in the 2nd testing times? 
 
  
 
 
CHAPTER 2 
THEORY AND METHODS 
 
2.1 Dose-Time-Response Models  
 
A family of three linear/nonlinear dose-response models with random effects (Zhu 
et al, 2003a,b.) were fitted to the Functional Observation Battery (FOB) and an 
automated motor activity data from the EPA/IPCS Collaborative Study (Moser et al, 
1997b). The three statistical models are Linear-Exponential, Complementary-Exponential 
and Toxico-Diffusion models. The first two are different forms of the diffusion model as 
briefly described below. The diffusion model describes the expected response as a 
function of dose and time:  
   Expected 
)exp(1
)exp(),(
tKCtd
tKBtdAdtfresponse
e
e
−+
−+==  
where t = testing time; d = administered dose, and B, C and Ke (“elimination rate”) are 
parameters to be estimated. A is the baseline level and can be time dependent.  If the 
coefficient C=0, we have the linear exponential model given by  
                          Expected )exp(),( tKBtdAdtfresponse e−+==   
Linearization of the diffusion model with respect to )exp( tKCtd e− via first order Taylor 
series expansion leads to the complementary exponential model:  
Expected )}exp(1){exp(),( tKCtdtKBtdAdtfresponse ee −−−+==  
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 In all three models the “elimination rate”  plays an important role. As t varies from 
[0, ),  f(t,d) attains an extreme value (either maximum or minimum depending on the 
sign of B) at t=1/ , then returns towards the baseline f(0,0). These three models are 
capable of modeling neurotoxic effects that are transient in time, with a common time of 
peak effects (TOPE) at t=1/K
eK
∞
eK
e irrespective of exposure level. Of the three, only the 
Linear-Exponential and Toxico-Diffusion were used as cases in this thesis. 
Another non-linear model that has never been fitted to the FOB data was also 
used in this thesis. Unlike the three models previously described, this model is non-
exponential and non-mechanistic in any sense. It is a simple rational function hence it is 
referred to as Rational Function model and is given by 
   2),( tK
BtdAdtfresponse ++==  
Here the TOPE is also independent of the exposure dose and is computed from estimable 
K parameter. As t varies from [0,∞ ), f(t,d) peaks to a maximum (B>0) at t = 
K (TOPE), then decreases back towards A. The inclusion of this non-exponential 
model would permit us to further examine the sensitivity of designs to the underlying 
models.   
 
2.2 TOPE Estimation 
Statistical modeling of a sample data such as the FOB data aims to capture and 
describe the underlying distribution of the data in an analytical way so that it is 
understandable and interpretable systematically. The TOPE, our parameter of interest, 
9 
 must be estimated directly from a model fit to the data. The reliability of the TOPE 
estimate depends upon both the statistical estimator and the experimental design.  
Ideally we would like expected value of the estimator to equal the parameter estimated; 
that is E(θ) ) = θ , where θ  is the population parameter and θ)  is the point estimator of θ .  
The point estimator is said to be unbiased if the bias B = E(θ) )-θ  = 0. In addition we 
would also prefer that the variation of the estimator V(θ) ) be as small as possible because 
a smaller variance indicates that under replications, a higher fraction of values of  θ)  will 
be “close” to θ . The overall accuracy of the point estimator θ)  can be characterized by 
the mean squared error (MSE) that combines variance and bias to form a single measure. 
   MSE(θ) ) = V(θ) ) + B2
Thus, assuming we know the true population dose-time-response trend, we can 
numerically measure the overall quality of a statistical estimator of the TOPE by 
computing both the bias and the mean squared error. However a statistical estimator and 
its properties generally depend on the experimental design that generates the data.  In the 
FOB tests, for example, the different sets of spacing of testing time will individually 
constitute different experimental designs that may lead to estimators with varying degree 
of bias (or lack of it) and mean squared error of the TOPE estimator.    
 
2.3 Testing Times and Dose-Time-Response Profiles 
Several factors can shape the profile or time trend of effects of acute exposure to 
potential neurotoxic chemicals. Such factors include the type of chemical agent, the 
administered dose (and route), the endpoint being measured and the timing of 
measurements. Timing is an important factor because effects of acute exposure to 
10 
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neurotoxic compounds usually have specific time profiles, with a certain window of time 
in which maximum effects can be observed (Zhu et al, 2003b). In the FOB protocol, the 
US EPA considered also these factors in their recommendation that the 2nd of four testing 
(the minimum required) be conducted at the estimated TOPE while the remaining three 
times of testing are fixed. The timing of the 2nd measurement can therefore vary 
depending mainly on prior knowledge, if any, of the TOPE of a particular chemical-
endpoint combination. 
 
2.4 Consideration for Optimal Design Theory 
2.4.1 General Principles 
According to Tobia (2004) a regression model may be used to investigate the 
relation between a response variable and a number of explanatory variables. In some 
cases one is able to choose the values of the explanatory variables, i.e. one can choose in 
which situations observations can be done. Such choice will determine the quality of the 
experiment. The theory of experimental design governs the quality of the experiment 
with respect to its effectiveness of providing relevant information about the model. 
Using the notation similar to Tobia (2004), let us consider a model with n 
explanatory variables x1,…,xn. Under a linear relationship the regression model is given 
by  
  Yi = β1 f1(Xi) + β2 f2(Xi) + …….+ βk fk(Xi) + εi ,  
and under a nonlinear relationship by  
Yi = f (Xi , β) + εi         
An observation Yi is the sum of the response function f (Xi , β) and error term εi , with 
 Xi = (xi1,…..xin) as the vector of the explanatory variables, and β = (β1,……, βk) as the 
vector of unknown parameters. The errors εi (i = 1,….., N) are, in the simplest case, 
assumed to have expectation of zero, constant variance, and to be uncorrelated: V (εi) = σ2 
and εi ~ N(0, σ2). 
Next, we can describe a design as follows. The m points in the experimental 
region where observations will be done are notated as X1*, X2*, ..., Xm*, where Xi* = (xi1, 
xi2, ..., xin). The number of observations at the point Xi* is notated as ni, so we have  
   
Nn
m
i
i =∑
=1
with an experiment notated as Еxper(N) where N indicates how many observations are 
done in the design, and 
   Еxper(N) = (X1*, …., Xm* ; n1 ,……, nm ; N) 
Under the linear model, the design matrix is N by k-matrix X where  
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For the least squares estimator  we have   ),.....,( 1 k
∧∧∧ = βββ
12 
 YXXX TT 1)( −
∧ =β   
where Y is the vector of observations, Y = (Y1 ,……,YN), M =XTX  is referred to as the 
information matrix and X is termed the design matrix. If the matrix M is not 
degenerative, then the matrix M-1(X; β, ε)σ2 = , is the dispersion 
matrix or the variance-covariance-matrix of the best linear estimator of  (Federov, 
1972).   
21)()( σβ −∧ = XXTCov
∧β
The information matrix depends on the choice of the design X and choosing an 
optimal design means that we have to choose an X, say X* , independent of β and error 
terms, which makes some real-valued function Φ{M (X)} as large as possible, that is best 
for all (β, ε). We can say that X* is Φ-optimal (Silvey, 1980).  
The D-, A-, E- and G-optimality are described briefly as follows.  
1. The D-criterion considers the generalized variance, i.e. the determinant of the 
information-matrix. So a D-optimal design is a design for which the determinant of the 
information-matrix is made as large as possible. 
2.  G-optimality is concerned with the variance of a predicted future observation at a 
given point xo : (1 + x0T(XTX)-1x0) σ2. The design objective is to minimize the variance.  
3.  A-optimality considers the trace of the matrix (XTX)-1. An A-optimal design 
minimizes the value of tr(XTX)-1  so that the sum of the marginal variances of the 
estimators is minimal. 
4.  E-optimality aims to maximize the eigenvalues of the matrix (XTX)-1. 
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 2.4.2 Optimal Design under Nonlinear Model 
Following the general principles for the linear regression, we now consider our 
example: Linear-exponential model, a nonlinear case with two predictor variables. The 
model yi = f(ti, di) = A + Bti di exp(-Keti) + εi
is given in section 2.1 and is a special case of the general nonlinear model  
Yi = f(Xi, β) + εi   
where β=(A , B, Ke) are unknown parameters. Note that the parameter Ke is of special 
interest because it determines the time of peak effect (TOPE); Xi is a vector of time ti and 
dose di  for the ith observation; and the error terms are independent normal with constant 
variance: εi ~ N(0, σ2).  
The problem of seeking estimates becomes more complicated when the function 
f(Xi, β) is non-linear in β. Using the Gauss-Newton method, a Taylor series expansion can 
be used to approximate the nonlinear regression model with linear terms and then employ 
ordinary least squares to estimate the parameters (Neter, 1996). Taking a first order 
Taylor approximation of mean response function f(X, β) at the estimate , we have  
∧β
Yi - (f(Xi , ) -  f
∧β ∧A 1(Xi , ) - ∧β ∧B  f2(Xi , ) -   f∧β ∧eK 3(Xi , )  
∧β
=  A  f1(Xi , ) + B 
∧β  f2(Xi , ) + K∧β e  f3(Xi , ) + ε∧β i
where   
j
j
ff β∂
∂= , 
and X is our experimental setting of t*d combination.  
 From the standpoint of numerical approximation, the design matrix is determined 
by f1(X, ),  f
∧β 2(X, ), and  f∧β 3(X, ), with ∧β
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    f1(X, β) = 1;  f2(X, β) = td exp(-Ket); and  f3(X, β) = -Bt2d exp(-Ket). 
 
Here we find that the function f2(X, β) includes Ke while f3(X, β) includes both Ke and B.   
Unlike in the case of linear regression model, the functions here are dependent on the 
parameters, and so is the design matrix. The implication is that the optimal design 
measures are actually dependent upon the true value of β as well as the model. The 
solution to optimal design is obtained iteratively and necessarily begin with initial or 
starting values for the regression parameters A, B and Ke .     
With the approximate approach, we have a design matrix D of partial derivatives 
now playing the role of the X matrix (Neter, 1996).  Similarly the form of D is 
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where  n1 = n2 =….. nm = 50, m = 4; and  1, 2, … m  correspond to t1, t2, t3, and t4.  
In a typical design setting without constraints, the least squares estimator  will 
be given as 
∧β
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    = (D
∧β TD)-1DTY  
where   is a vector of the least squares estimated regression coefficients. The variance-
covariance matrix of   is 
∧β
∧β
  Var( ) = (D
∧β TD)-1 σ2
In this case therefore we are looking for designs D* which will maximize the optimality 
function Φ{M (D), β }, that is, D* may depend on β  other than through the information 
matrix only. Although it could be problematic, the initial or starting values for the 
parameters would have to be found. 
 In this thesis, optimal design takes some special constraints. We are interested 
only in designs with second testing time t2 to be determined while everything else is 
fixed. In defining our experimental region, we are constrained by the FOB design 
protocol so we will focus on finding the optimum timing of 2nd of four repeated 
measurements with the rest three testing times fixed. Five dose groups with their dose 
values were pre-decided. Therefore we define our experimental region as follows:  
t = 0, t2, 24, 168; where 0< t2 =< 20 
d = 0, 0.75, 1.5, 3.0, and 6.0 
Also we want to be able to allow for dose group-specific variances. 
In summary, the design considered here is a special case in which we maximize 
C’MC. The C matrix selects particular components of the co-variance matrix. Our focus 
of interest is to find an optimal design D{f(Ke)}* for the purpose of estimating TOPE as a 
function of one of the unknown model parameters Ke while acknowledging that this 
optimality is also dependent on the parameters β. In addition we would like the optimal 
16 
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design to accommodate heteroscedasticity. However, instead of seeking algorithms that 
would enable us to construct the appropriate design measures, we opted for a relatively 
more empirical approach by doing simulation studies. 
 
2.5 Simulation Rational  
In order to evaluate a design, we assume an underlying dose-time-response 
relationship is given and we generate data according to the dose-time-response 
relationship and normal random error. The data are simulated under a chosen design. The 
simulated data are then used to estimate the model parameters under which simulation 
was done. 
A number of experimental designs are possible with respect to the choice of dose 
and time. However, these designs vary in their capability of revering the information 
about the true parameters. Thus, we wished to perform a test to determine which of these 
different designs would produce the best estimate(s) of the population parameters.  Our 
target parameter was the time of peak effects (TOPE). For this purpose, we simulated 
different designs by generating the FOB data based on the “true” model. An efficient 
design should allow estimation of the parameters to yield estimates as close to the true 
value as possible and as reliable as possible. For every simulated design, we fitted the 
same true model to the data via nonlinear mixed-effects modeling to obtain an estimate of 
TOPE. The simulation and model fitting process were replicated N times under each 
design.  
The designs which produced the best TOPE estimates were determined based on 
the bias and mean squared error (MSE) statistics obtained from replicated estimates.  The 
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efficiency of each design was evaluated with specific optimality criteria as follows. The 
absolute relative bias must be less than 5% of underlying TOPE and/or the design must 
be associated with the minimum MSE.  The minimum MSE was determined both by 
computation and graphical illustrations. We placed more emphasis on the MSE as a 
single measure because it combines the effect of bias and sampling variation of the 
estimator. We applied the concept of coefficient of variation (CV) to relate the MSE to 
the underlying TOPE. We therefore devised a modified coefficient of variation (mCV) 
which was computed as a ratio of squared root MSE to the underlying TOPE. This 
measure was used to compare the variability of different designs based on 2000 
replications for each design. Practical designs were determined as those of minimum 
mCV and/or mCV of no more than 15%.   
 
2.6 Experimental Designs 
We employed a number of different experimental designs that essentially were 
variants of the EPA/IPCS Collaborative Study design (Moser et al, 1997a). These designs 
differ only with respect to the 2nd testing time point. The design for each acute exposure 
experiment in the EPA/IPCS Collaborative Study was as follows: 
Sample size = 50 rats:  5 dose groups with 10 rats per group 
Testing times per rat: t1 = 0 hr, t2 = TOPE (hr), t3 = 24 hr, t4 = 168 hr 
Total number of observations = 200 
 In line with the EPA/IPCS study protocol above, we fixed the dose levels and also 
fixed the three testing times t1, t3, and t4 at baseline, 24 and 168 hours post exposure 
respectively. In order to investigate how the choice of second testing time would affect 
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the estimation of TOPE, we let t2 vary between designs. Specifically, a sequence of 30 
different designs was chosen with t2 values ranging between 0.2 hr and 20 hr. Table 2.1 
illustrates the EPA/IPCS Collaborative Study design and three of thirty test designs (first, 
second and thirtieth). It means that the designs allowed for comparison with the one that 
used the true TOPE as its 2nd testing time.   
 
Table 2.1 Testing Times for EPA/IPCS Collaborative Study Design  
and Candidate Designs  
 
Testing 
Times 
EPA/IPCS 
Study Design 
Design 
#1 
Design 
#2 
……. Design 
#30 
t1 0 hr 0 hr 0 hr …… 0 hr 
t2 Estimated 
TOPE (hr) 
0.2 hr 0.4 hr …… 20 hr 
t3 24 hr 24 hr 24 hr …… 24 hr 
t4 168 hr 168 hr 168 hr …… 168 hr 
 
Table 2.2 shows all the 30 unique designs represented by the table columns, and 
of which their t2 range from 0.2hr to 20hr. These designs were applied to three dose-time-
response models coupled with different combinations of functional domain and 
experiment (or chemical). 
Three dose-response models were considered: Linear-Exponential, Toxico-
Diffusion (Zhu et al, 2003a) and Rational Function models. Parameter values were taken 
from previous models fit to the real datasets (Zhu et al. 2003a,b), except for the Rational 
Function model to which reasonable parameter values were simply assigned. Simulations 
were based on the following three selected combinations of design, response variable, 
and model:  
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1. Acute TET exposure experiment / Linear-Exponential model / Activity domain 
composite score 
2. Acute DDT experiment / Toxico-Diffusion model / Neuromuscular domain 
composite scores  
3. Acute TET exposure experiment / Rational Function model / Activity domain 
composite scores  
 
Table 2.2 Table of Four Testing Times1 (Hours) by Thirty Different Designs2
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
t1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
t2 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2 2.5 3 3.5 4 5 
t3 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 
t4 168 168 168 168 168 168 168 168 168 168 168 168 168 168 168
 
 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 
t1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
t2 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
t3 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 
t4 168 168 168 168 168 168 168 168 168 168 168 168 168 168 168
 
1.  Testing times designated as t1, t2, t3 and t4 occur at 0hr, t2, 24hr and 168hr respectively. 
2.  The designs numbering from 1 to 30 are designated by their respective t2 ranging from 0.2hr to 20hr 
 
2.7 Simulation Steps 
Our simulation scheme is illustrated below using the first combination: Activity 
domain scores in conjunction with the Linear-Exponential model. Simulations of the 
other two combinations were conducted similarly.  
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2.7.1 Step 1: Define the Dose-Response Model and Population Parameters 
 Table 2.2 was taken from Zhu et al (2003b) and it shows the results of the Linear-
Exponential model fit to the Activity domain composite scores from the acute TET 
experiment of the EPA/IPCS Collaborative studies (Moser et al, 1997b). We assumed 
that the fitted model represents a true dose-response relationship in a hypothetical 
population of rats, that is, the estimated model parameters were taken as the true values 
for this population.  
Based on this “true” model, the TOPE equals 1/ Ko  (= 6.16 hrs). The model 
specification accommodates heteroscedasticity with dose-specific standard error given by  
0.2822, 0.2822*1.2884, 0.2822*1.3858, 0.2822*1.2953, 0.2822*2.548 for the five groups 
of dose=0, 0.75mg, 1.5mg, 3.0mg,  and 6.0mg, respectively. The model also contains a 
random intercept (standard error= 0.1697) for each rat to allow for between-rat variation.  
 
Table 2.3 Acute TET Exposure Study: Activity Scores with 
Linear Exponential Model1,2 Fit 
 
Parameter Value Std.Error DF t-value p-value 
      
A 1.2738 0.0412 147 30.9129 <.0001 
B 0.1755 0.0211 147 8.3261 <.0001 
K 0.1623 0.015 147 10.8451 <.0001 
Variance Estimate 
Dose 0 0.75 1.5 3 6 
StdErr 1 1.2884 1.3858 1.2955 2.5479 
Random effects A Residual    
Std Dev 0.1697 0.2822    
Model Selection 
Criteria: AIC BIC logLik   
 248.3158 277.9555 -115.1579   
  
1. Model=A+B*dose*time*exp(-Ke*time) 
2. Distinct variance assumed for each dose group, and the dose-specific standard error is in 
proportion to that of control  
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2.7.2 Step 2: Generate Datasets for Each Design 
For each design, we simulated an experiment consisting of 10 rats in each of five 
dose groups. Each rat was tested at 4 time points yielding a total of 200 observations in 
each experiment. Data were generated based on the following mixed-effects model:   
   yijk  = f(θik, dosei, timej) + errorijk  , i = 1,2,..5;  j = 1,2,3,4,  k = 1,2…10   
In the model θik includes also random effects (intercepts) that are additive to the 
population parameters. The response values were obtained by evaluating the function at 
the true parameter values, simulated random effects, and the design points of dose and 
time given in Tables 2.2 & 2.3. The final outcome values were obtained by further adding 
to the response values the simulated random effects and errors. For the linear exponential 
model, for example, the outcome is,  
yijk  =A+aik+B*dosei*timej*exp(-K*timej)+errorijk  
 Simulations of random effects and errors were accomplished by using computer 
generated random numbers from specified distributions as follows:  
Random effects: This is unique to individual rat. Therefore for 50 rats, 50 random 
numbers were generated from a normal distribution with zero mean and standard 
deviation=0.1697 corresponding to that of random intercepts from the fitted model (table 
2.2).   
Random error and heteroscedasticity:  Random error is associated with individual 
observation and variances are unique to individual dose groups. Therefore, for 40 
observations in each of 5 dose groups, 40 random numbers were generated from a normal 
distribution with a zero mean and standard deviation specific for that dose-group.  
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Replication: We replicated N=2000 datasets under each design. N was established by 
allowing it to increase until fitted TOPE was stable. We found N = 2000 satisfactory for 
all designs in this study.  
 
2.7.3 Step 3: Estimate Parameters 
The underlying model was fitted to each simulated dataset to get estimates for 
parameters A, B and K. TOPE was computed from the estimate of K (TOPE = 1/K). This 
simulation process resulted in a sample of estimates (2000 replications, convergence rates 
of about 80% or greater) for each of A, B, K, and the TOPE. Based on this sample 
estimates, the followings were computed  
Bias  = sample mean of the TOPE estimates – the “true” TOPE,  
Mean Squared Error (MSE)  =  Bias2 + Sample Variance of the TOPE Estimates,  
Relative bias  =  100*bias/true TOPE 
and  
Modified coefficient of variation (mCV) = 100*sqrt(MSE) / true TOPE 
 
2.7.4 Case Large Variance 
 In order to see the impact of random error on the design, the simulation procedure 
(Steps 1-4) was repeated for the TET/Activity/Linear-Exponential model setting 
employing larger variation (StdErr=2.0; 78-82% convergence). This illustrative example 
would enable us to evaluate each study design for this experiment under extreme 
variability of population dose response profiles.  
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2.8 Simulation under Two Additional Models  
Simulation was conducted for two additional models: Toxico-Diffusion model 
and Rational Function model. This would allow us to evaluate the sensitivity of designs 
across model types. The followings are specific information about the models derived 
from previously fitting the Toxico-Diffusion model to the real data and from simply 
assigning parameter values to the Rational Function model.  
 
 
2.8.1 Toxico-Diffusion Model: Acute DDT Experiment / Neuromuscular Domain 
  
Here we had the opportunity to explore a different member of the same family of 
models as well as a different exposure agent and neurobehavioral domain. Table 2.4 
taken from Zhu et al (2003b) shows the toxico-diffusion model fit to the commonality 
scores of the neuromuscular domain in the acute DDT experiment.  The estimated 
parameter values were used to simulate data under the toxico-diffusion model. From the 
table, the TOPE estimate directly computed from 1/K is 4.7hr. This value was assumed to 
be the ‘true’ TOPE parameter for this setting. 
 
2.8.2 Rational Function Model: Acute TET Experiment / Activity Domain  
This model is a simple rational function developed solely for the purpose of this 
thesis. Unlike the other two models, it was never before fitted to the real FOB data. The 
reason for inclusion of the model was to further examine the sensitivity of designs to 
models. In using this model, we were able to assign parameter values such that 1) the 
model reasonably describes a dose-time-response profile similar to that observed in the 
original FOB data, and 2) we would have the opportunity to fit a model to simulated 
 datasets from a population profile with a relatively small ‘true’ TOPE of 2 hr, the value 
recorded in the pilot study of the acute TET experiment. (Moser et al, 1997b) 
The Rational Function model was specified as follows: 
model  = A + B*dose*time/(K + time2), where TOPE = K  
Two sets of population parameters and sigma were simulated and fitted with Rational 
Function model as specified in the Table 2.5. The set of parameters (Case 1) describes a 
response profile similar to that of the exponential model fit to TET/activity scores from 
the highest dose group. The second set (Case 2) describes still a similar profile but the 
‘true’ TOPE is set lower at 2hr.   
 
 Table 2.4   Toxico-diffusion Model1,2 fit to Neuromuscular Scores of 
Rats Exposed to DDT3 
 
Parameter  Value Std.Error DF  t-value  p-value 
A 1.3388 0.0307 147 43.57   <.0001 
B 0.0187 0.0073 147 2.58  0.0109 
C 0.0108 0.00667 147 1.61   0.1089 
Ke 0.2129 0.0327 147 6.52   <.0001 
Variance Estimate           
Dose Group 0 10.9      21.8      43.5        87 
StdErr 1 0.8859 1.0332 1.6252 1.2037 
Random effects A:           
  Intercept Residual       
StdDev: 0.1042 0.2785       
 
1. Model=A+B*Dose*Time*exp(-Ke*Time)/ (1+C*Dose*Time*exp(-Ke*Time)) 
2. Distinct variance assumed for each dose group, and the dose-specific standard error is in 
proportion to that of control  
3. The IPCS/EPA Collaborative Study 
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Table 2.5 Rational Function Model Specifications 
Parameter coefficients  
A B K 
 
Sigma (σ) 
 
TOPE (hr) 
Case 1 1.27 5.167 37.95 1.0 6.16 
Case 2 1.25 1.67 4 0.3 2 
 
 
In Figure 2.1 the Linear-Exponential (LE) and Rational Function (RF) models are 
compared by their theoretical dose-response profiles for a fixed dose. In the Figure, plot 
A displays the theoretical curve for the LE model fit to the Activity scores for the highest 
dose group in the acute TET experiment (Moser et al, 1997b; Zhu et al, 2003b). Plots B1 
& B2 (Figure 2.1) are the dose-response profiles as described by RF model under the 
assigned parameter values of Case 1 and Case 2, respectively.  
In the simulations, the two cases of RF model were used as the base models. The 
standard deviation was specified as σ = 1.0 across all dose groups in Case 1 where 
TOPE=6.12 hr. In Case 2 with TOPE=2.0 hr we specified σ = 0.3. 
 
 Figure 2.1 Theoretical Response-Time Profiles for the Highest Dose1 Group 
Based on Comparison Models2: Activity Scores of Rats Exposed TET 
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B2.  Rational Function Model: TOPE = 2 hr 
 
1.  Maximum exposure dose was 6 mg in the acute TET experiment of IPCS/EPA Collaborative 
Study (Moser et al, 1997b) 
2. Linear-Exponential Model = A+B*dose*time*exp(-Ke*time): (A, B, Ke ) = (1.27, 0.17, 0.16) 
 Rational Function Model = A + B*dose*time/(K + time^2):  
(A, B, K ) = (1.27, 5.167, 37.95) for TOPE=6.16 hr 
  (A, B, K ) = (1.25, 1.67, 4) for TOPE = 2 hr 
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CHAPTER 3 
RESULTS 
 
3.1 Acute TET Experiment: Activity Domain / Linear-Exponential Model 
The simulation results are summarized here in this section according to the pattern 
of standard deviation. Two variance patterns were simulated. In the first category the 
random effect and dose group specific random errors in the original fitted data were 
simulated.  Specifically, the standard deviations were 0.28, 0.36, 0.39, 0.37, and 0.72 for 
the five dose groups respectively. In the second category, a large constant value of 
standard deviation was set at 2.0 for all dose groups.  
 
3.1.1 Distribution of TOPE Estimates 
 The rate of convergence among 2000 replications was recorded for each of the 30 
designs. The convergence rate was greater than 95% in all cases.  
Thirty boxplots (one boxplot of 2000 TOPE estimates per design) are displayed 
graphically side-by-side in Figure 3.1 to show the spread of TOPE estimates for 
individual designs. The designs with t2 between about 0.5 hr and 6 hr appeared to have 
relatively smaller spread for the TOPE estimates. As the second testing time point 
continues to increase beyond the underlying TOPE=6.16 hr, the TOPE estimator becomes 
more variable. These findings suggested that the designs which have their 2nd testing 
times at or before the TOPE are robust to the estimation of TOPE.    
 Figure 3.1 Boxplots of TOPE Estimates1 Across Designs2 for Acute TET 
Experiment: Simulated Activity Scores3
with Linear-Exponential Model Fit 
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 1.  One boxplot per design with 2000 replications of TOPE estimates  
 2.  Each of 30 designs is designated by the value of its 2nd time of testing along y-axis 
3.  Simulated variance pattern is equivalent to that obtained from the original FOB data: different 
variance per dose group (σ = 0.28, 0.36, 0.39, 0.37, and 0.72), random intercept per subject (σ = 
0.17). 
The limits of x-axis have been reduced for clarity. 
 
Figure 3.2 shows bias (A) and relative bias (B) of the TOPE estimator. It is seen 
here that the relative bias of TOPE estimates was less than 5% for the designs with t2 of 
0.6 - 15 hr and was greater than 5% but less than 10% for designs with t2 between 0.6 and 
17 hr. Furthermore, the Figure also shows a likely positive bias associated with t2 that is 
either much smaller or larger than the underlying TOPE. 
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 Figure 3.2 Bias and Relative Bias of TOPE Estimates1 across Designs for Acute 
TET Experiment: Simulated Activity Scores2
with Linear-Exponential Model Fit 
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1.  Bias for each design is computed using the mean of 2000 replicates of TOPE estimates. 
Relative bias = 100*bias/true TOPE. 
2.  Simulated variance pattern is equivalent to that obtained from the original FOB data: different 
variance per dose group (σ = 0.28, 0.36, 0.39, 0.37, 0.72), random intercept per subject (σ = 0.17). 
 Each of 30 designs is designated by the value of its 2nd time of testing along the x-axis. 
 Vertical Dash-dot line passes through 2nd testing time at the true TOPE (6.16 hr). 
 Horizontal dashed-lines from bottom mark 0%, 5% and 10% relative bias (B). 
 Vertical axis of B has been reduced to enhance clarity. 
 
From Figure 3.1 we observe that the distributions of TOPE estimates for the 
designs appear to be normal when t2 values are in the mid-range but are likely positively 
skewed when t2 is smaller or larger. When a distribution is positively skewed, its mean is 
greater than the median and the median then becomes a more robust measure of the 
center of the distribution. Therefore the profile of the median TOPE estimates in Figures 
3.1 & 3.3 provides a supplementary picture of potential bias of TOPE estimates across 
designs.  
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Figure 3.3 Median TOPE Estimates1 across Designs for Acute TET Experiment: 
Simulated Activity Scores2 with Linear-Exponential Model Fit 
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1.  Median of 2000 replicates of TOPE estimates. 
2.  Simulated variance pattern is equivalent to that obtained from the original FOB data: different 
variance per dose group (σ = 0.28, 0.36, 0.39, 0.37, 0.72), random intercept per subject (σ = 0.17). 
 Each of 30 designs is designated by the value of its 2nd time of testing along the x-axis. 
 Dash-dot line marks the true TOPE (6.16 hr). 
 Dotted lines mark the upper and lower 5% margins of underlying TOPE. 
 
Coefficient of variation (mCV) is plotted against designs in Figure 3.4. Plot A 
displays values corresponding to the whole t2 spectrum (i.e. all designs) while in plot B 
the focus is on designs with t2 less than 10 hr. The lowest mCV of 11.3% (corresponding 
to the lowest MSE of 0.481) was associated with the design of t2 = 2 hr. However those 
designs with t2 between 1 and 7 hours had mCV less than 15% (Figure 3.4B) and these 
designs were most precise in their estimation of TOPE.  
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 Figure 3.4 Plots of Coefficient of Variation (mCV)1 Across Designs 2  
for Acute TET Experiment: Simulated Activity Scores3
with Linear-Exponential Model Fit
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1.  MSE for each design was computed from the mean and the variance of 2000 replicates of 
TOPE estimates. mCV = 100*sqrt(MSE) / true TOPE 
2.  Plot A displays all 30 designs. The upper limit of y-axis has been reduced in plot B for clarity. 
3.  Simulated variance pattern is equivalent to that obtained from the original FOB data: different 
variance per dose group (σ = 0.28, 0.36, 0.39, 0.37, 0.72), random intercept per subject (σ = 0.17). 
 Vertical Dash-dot line passes through 2nd testing time at the true TOPE (6.16 hr). 
 
 
3.1.2 Distribution of TOPE Estimates: Large Variance  
 The case of large variability in dose response was also considered in order to 
assess the impacts that such large variability might have on designs. We specified a large 
constant variance (σ = 2.0) across all dose groups in the true model. This was expected to 
be a challenge to modeling considering that this variation constituted about three times 
the standard deviation (σ = 0.72) of the most variant dose group in the original dataset. 
Expectedly, relatively low percent convergences (68-78%) were recorded for the designs 
associated with both smaller and larger values of the second test times. However designs 
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with t2 values of between 0.6 hr and 15 hr recorded convergence fractions of between 
78% and 82%.  
 
Table 3.1 Convergence across Designs1for Acute TET Experiment:  
Simulated Activity Scores (Large Variance)2 with 
Linear-Exponential Model Fit 
 
Design (t2 (hr)) 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2 
Convergence (%) 69 76.95 78.45 78.35 76.25 78.45 78.5 79.3 81.05 80.1 
           
Design (t2 (hr)) 2.5 3 3.5 4 5 6 7 8 9 10 
Convergence (%) 79.1 80.2 80.85 79.6 78.95 80 80.55 81.5 79.05 80.8 
           
Design (t2 (hr)) 11 12 13 14 15 16 17 18 19 20 
Convergence (%) 80.25 80 78.9 79.7 79.55 76.7 76.65 74.6 71.85 68.9 
 
 1.  Each design is designated by the value of its 2nd time of testing. 
 2.  Constant variance (σ = 2.0) across dose groups 
 
 
 In Figure 3.5 we see that the median TOPE estimates were within 5% margin of 
the true TOPE only for designs with t2 of 0.4 to 0.6 hr. We also see from the figure that 
the median estimates were within about the 10% margin for designs with t2 of less than 
about 10 hr. On the other hand, Figure 3.6 shows that all of the designs were positively 
biased in their estimation of TOPE; the bias was about 10% above the underlying TOPE 
when t2 was between 2 and 5 hr. 
Figure 3.7 reveals that the replicated TOPE estimates were generally positively 
skewed for designs with larger and smaller (to a less extent) values of t2. Because of the 
positive skewness, the means were generally greater than the medians and this may offer 
an explanation for some disparity in profiles across designs seen from Figures 3.5 and 
3.6. The bias displayed in Figure 3.6 may be due in part to the skewness of the 
 distributions and, as a result, the profile of median estimates shown in Figure 3.5 may 
provide complimentary information. 
 
 
Figure 3.5 Median TOPE Estimates1 Across Designs2 for Acute TET 
Experiment: Simulated Activity Scores (Large Variance)3 
with Linear-Exponential Model Fit 
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1.  Median of 2000 replicates of TOPE estimates. 
2.  The designs are designated by the values of their 2nd time of testing along the x-axis. 
 3.  Constant variance (σ = 2.0) across dose groups 
 Dash-dot line marks the true TOPE (6.16 hr). 
Dotted lines (from bottom) mark the lower 10%, 5%, and upper 5% and 10% margin of the 
underlying TOPE.  
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Figure 3.6 Bias & Relative Bias of TOPE Estimates1 Across Designs2
for Acute TET Experiment: Simulated Activity Scores 
(Large Variance)3 with Linear-Exponential Model Fit
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1.  Bias for each design was computed using the mean of 2000 replicates of TOPE estimates. 
Relative bias = 100*bias/true TOPE. 
2.  The 30 designs (not all is shown on these plots) are designated by the value of their 2nd time of 
testing along the x-axis. 
 3.  Constant variance (σ = 2.0) across dose groups 
 Dash-dot line passes through 2nd testing time at the true TOPE (6.16 hr). 
 Dotted-lines mark intervals on x-axis. 
Limits of both axes in plot B have been reduced to enhance clarity. 
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Figure 3.7 Boxplots of TOPE Estimates1 Across Designs2 for Acute TET 
Experiment: Simulated Activity Scores3 (Large Variance) 
with Linear-Exponential Model Fit 
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 1.  One boxplot of 2000 replications of TOPE estimates per design 
 2.  Each of 30 designs is designated by the value of its 2nd time of testing along y-axis 
 3.  Constant variance (σ = 2.0) across dose groups 
Upper limit of x-axis has been reduced for clarity. 
 
It should be noted, however, that on the downside, the estimates from these 
designs were associated with relatively wide spread. The mCV profile of all designs 
shown in Figure 3.8A and the expanded form in Figure 3.8B both appear to indicate that 
designs with t2 ranging from 2.5 hr to 6 hr are associated with the lowest mCV’s with the 
minimum value of 32.4% occurring at t2 of 5 hr. Although the mCV trend within this t2 
range (2.5 - 6 hr) appears to be unstable (Figure 3.8B), the smallest spread coupled with 
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 least skewness have been demonstrated for designs in this t2 range. In contrast, the mCV 
is about three times as large as the case of small variance (refer to section 3.1.1). 
 
Figure 3.8 Coefficient of Variation (mCV)1 Across Designs2 for Acute 
TET Experiment: Simulated Activity Scores3 (Large Variance) 
with Linear-Exponential Model Fit 
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1.  MSE for each design was computed from the mean and the variance of 2000 replicates of 
TOPE estimates. mCV = 100*sqrt(MSE) / true TOPE 
2.  Designs with mCV larger than 100% were excluded in this figure for better display of mCV 
3.  Constant variance (σ = 2.0) across dose groups compared to most variant dose group (σ = 0.7) 
in original data. 
Vertical dash-dot line passes through 2nd testing time at the true TOPE (6.16 hr). Dotted lines form 
grids to aid data point localization. 
  
 
3.2 Acute DDT experiment: Neuromuscular Domain/ Toxico-Diffusion Model 
 
 The DDT experiment is another experiment of the IPCS/EPA Collaborative Study 
(Moser et al, 1997b). The population parameters, plus random and error variances were 
obtained from the results (refer to Table 2.4) of a prior fit of the Toxico-Diffusion model 
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to the dataset (Zhu et al, 2003b). Accordingly, dose group specific variances (σ = 0.28, 
0.25, 0.29, 0.45, 0.34) were employed for simulation. 
Since the underlying TOPE in the DDT experiment was 4.7 hr, the spacing of t2 
was slightly modified here. A total of 31 designs with t2 ranging from 0.2hr to 17hr were 
employed in this phase (Table 3.2). The convergence rate was greater than 96% for all 
simulated designs when fitting with the Toxico-Diffusion model.  
 
Table 3.2 Table of Designs with Unique 2nd Testing Times 
for Acute DDT Experiment 
 
design # 1 2 3 4 5 6 7 8 9 10   
2nd test time 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2   
                        
design # 11 12 13 14 15 16 17 18 19 20   
2nd test time 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7   
                        
design # 21 22 23 24 25 26 27 28 29 30 31
2nd test time 7.5 8 9 10 11 12 13 14 15 16 17
 
 
Figure 3.9 again shows the median TOPE estimates for all designs, which were 
consistently within 5% margin of the underlying value of 4.7hr. The relative bias (Figure 
3.10) was less than 5% for t2 between 0.4 hr and 12 hr,  and less than 10% for t2 between 
0.2 hr and 14 hr; for  t2 = 15 hr and beyond, the bias became increasingly large, reaching 
more than 30% at t2 = 17 hr. 
Figure 3.11 shows that the distribution of TOPE estimator here is not much 
different from the previous boxplots (refer to Figure 3.1). Figure 3.12 clearly 
demonstrates that the designs with t2 fixed at 0.8 - 4 hr were associated with mCV of 15% 
or less.  
 Figure 3.9 Median TOPE Estimates1Across Designs2 for Acute DDT 
Experiment: Simulated Neuromuscular Scores3 with  Toxico-Diffusion Model Fit 
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1.  Median of 2000 replicates of TOPE estimates. 
 2.  Each design is designated by the value of its 2nd time of testing along the x-axis. 
3.  Simulated variance pattern is equivalent to that obtained from the original FOB data: different 
variance per dose group (σ = 0.28, 0.36, 0.39, 0.37, 0.72), random intercept per subject (σ = 0.10). 
Dash-dot line marks the true TOPE (4.7 hr). Dotted lines (from bottom) mark the lower and upper 
5% margins of the true TOPE.  
 
Figure 3.10. Relative Bias of TOPE Estimates1Across Designs2 for Acute DDT 
Experiment: Simulated Neuromuscular Scores3 with Toxico-Diffusion Model Fit 
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1.  Bias for each design was computed using the mean of 2000 replicates of TOPE estimates. 
2.  The  designs are designated by the value of their 2nd time of testing along the x-axis. 
3.  Simulated variance pattern is equivalent to that obtained from the original FOB data: different 
variance per dose group (σ = 0.28, 0.36, 0.39, 0.37, 0.72), random intercept per subject (σ = 0.10). 
 Dash-dot line marks the true TOPE (4.7 hr). 
Dotted lines (from bottom) mark the 0%, 5% and 10% margins of the true TOPE.  
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Figure 3.11 Boxplots of TOPE Estimates1 Across Designs2  
for Acute DDT Experiment: Simulated Neuromuscular Scores3  
with Toxico-Diffusion Model Fit 
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 1.  One boxplot per design with 2000 replications of TOPE estimates  
 2.  Each of 31 designs is designated by the value of its 2nd time of testing along y-axis 
3.  Simulated variance pattern is equivalent to that obtained from the original FOB data: different 
variance per dose group (σ = 0.28, 0.36, 0.39, 0.37, 0.72), random intercept per subject (σ = 0.10). 
Upper limit of x-axis has been reduced to aid visualization. 
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 Figure 3.12  Plots of Coefficient of Variation (mCV)1 Across Designs2 for Acute 
DDT Experiment: Simulated Neuromuscular Scores3 with Toxico-Diffusion Model 
Fit 
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1.  MSE for each design was computed from the mean and the variance of 2000 replicates of 
TOPE estimates. mCV = 100*sqrt(MSE) / true TOPE. 
2.  Only plot A displays all the 31 designs. The upper limits of both axes have been reduced in plot 
B for better display of mCV. 
3.  Simulated variance pattern is equivalent to that obtained from the original FOB data: different 
variance per dose group (σ = 0.28, 0.36, 0.39, 0.37, 0.72), random intercept per subject (σ = 0.10). 
Vertical dash-dot line passes through 2nd testing time at the true TOPE (4.7 hr). Dotted lines form 
grids to aid localization of data points. 
 
 
 
3.3 Acute TET Experiment/ Activity Domain:  Rational Function Model  
 
This model is based on rational function that may also be used to describe a dose-
response profile similar to those demonstrated by the Activity domain in the acute TET 
experiment. The main purpose of using this model is to test sensitivity of design with 
respect to models, particularly with an underlying TOPE as small as 2 hr. 
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   Two sets of population parameters and sigma were simulated. For the first case, 
TOPE = 6.16 hr and standard deviation was specified as σ = 1.0 across all dose groups. 
The standard deviation was about 40% larger than that of  the most variant dose group (σ 
= 0.28*2.55 = 0.71) from the original dataset (Table 2.2). The second case had TOPE = 2 
hr with σ = 0.3 for every dose group. In each of both simulations, the convergence rate of 
fitting simulated data was greater than 80% under designs of t2 values less than 10 hr 
(Figure 3.13A, case 1) and 3.5 hr (Figure 3.13B, case 2).  
 
Figure 3.13 Convergence across Designs1: Simulated Activity Scores2  
of the Acute TET Experiment With Rational Function Model Fit 
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 1.  Each of 30 designs is designated by the value of its 2nd time of testing along the x-axis. 
2.  Sigma equals 1.0 for A and 0.3 for B. 
Vertical dash-dot line is the underlying TOPE. 
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 Since in each instance the t2 range associated with good convergence stretches 
beyond the underlying TOPE reasonably well in both directions, there is sufficiently wide 
time window within which to reliably test candidate designs. Therefore non-convergence 
is not a problem. 
 
3.3.1  Rational Function Model: Case One  
 
 
 Figure 3.14 shows that the spread of the replicated TOPE estimates is relatively  
  
Figure 3.14  Boxplots of TOPE Estimates1 to Compare Designs2 for Acute 
TET Experiment: Simulated Activity Scores3 (TOPE = 6.16 hr) 
With Rational Function Model Fit 
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 1.  One boxplot per design with 2000 replications of TOPE estimates  
 2.  Each of 30 designs is designated by the value of its 2nd time of testing along y-axis 
3.  Simulated total variance is 1.0 (control group variance for the original FOB data = 0.6) 
Upper limit of x-axis has been reduced for clarity. 
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 small, apparently between 1 hr and 5 hr. The median increasingly shifted to the right 
(increased) starting from t2 greater than about 9 hr but shifted to the left (decreased) when 
t2 was less than about 0.6 hr. In addition, for both of these extreme t2 values, the 
skewness increased and the variability of the TOPE estimator became increasingly large. 
 
Figure 3.15  Median TOPE Estimates1 by Designs for 
Acute TET Experiment: Simulated Activity Scores2 (TOPE=6.16 hr) 
with Rational Function Model Fit 
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1.  Median of 2000 replicates of TOPE estimates. 
2.  Simulated constant variance per dose group (σ= 1.0). 
 Each of 30 designs is designated by the value of its 2nd time of testing along the x-axis. 
 Dash-dot line marks the true TOPE (6.16 hr). 
Dotted lines mark the upper and lower 5% & 10% margins of the true TOPE.  
 Upper limit of y-axis has been reduced for clarity. 
 
 
In Figure 3.15, the median TOPE estimates for designs within the t2 ranges of 0.2- 
8 hr and 0.2- 9 hr are shown to be within the 5% and 10% margins of the underlying 
TOPE respectively. For the bias, Figure 3.16 shows that the relative bias was no more 
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 than 5% and 10%  for t2 in the ranges of 1.4 - 8 hr and 1.2 - 9 hr respectively. The mCV 
for all designs tested were greater than 15% while a lowest mCV of 18.4% was recorded 
for t2 of 2.5 hr (Figure 3.17).  
 
 
Figure 3.16 Relative Bias of TOPE Estimates1 Across Designs2 for 
Acute TET Experiment: Simulated Activity Scores (TOPE=6.16 hr) 
with Rational Function Model Fit 
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1.  Bias for each design was computed using the mean of 2000 replicates of TOPE estimates. 
2.  Thirty designs are designated by the value of their 2nd time of testing along the x-axis. 
Vertical dash-dot line passes through 2nd testing time at the true TOPE (6.16 hr) while dotted lines 
form grids to aid data point localization. 
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 Figure 3.17 Plots of Coefficient of Variation (mCV)1 Across 30 Designs 2 of Acute 
TET Experiment: Simulated Activity Scores3 with TOPE=6.16 hr 
and Rational Function Model Fit 
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1.  MSE for each design was computed from the mean and the variance of 2000 replicates of 
TOPE estimates. mCV = 100*sqrt(MSE) / true TOPE. 
2.  Designs are designated by the value of their 2nd time of testing along the x-axis. All 30 designs 
are displayed in A while in B the upper limits of the x- and y-axes have been reduced for clarity. 
3.  Simulated constant variance per dose group (σ= 1.0). 
Vertical dash-dot line passes through 2nd testing time at the true TOPE (6.16 hr). Dotted lines form 
grids to aid data point localization. 
 
 
 
3.3.2  Rational Function Model: Case Two 
 
 Inspection of Figures 3.18 and 3.19A reveals a progressive shift of the median 
estimate away from the underlying TOPE as t2 increased from 2 hr. As t2 increased, the 
spread and skewness of the replicated TOPE estimates also increased. Quantitatively, the 
median TOPE estimates were within the 5% and 10% margins of the true value when t2 
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 was no greater than 2.5 hr and 3 hr respectively (Figure 3.19 A). However those designs 
of which t2 values were 0.2 - 3 hr produced estimates with no more than 5% relative bias. 
(Figure 3.19 B). 
 
 
Figure 3.18  Boxplots of TOPE Estimates1 to Compare Designs2 for Acute 
TET Experiment: Simulated Activity Scores3 (TOPE = 2 hr) 
With Rational Function Model Fit 
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 1.  One boxplot per design with 2000 replications of TOPE estimates  
 2.  Each of 30 designs is designated by the value of its 2nd time of testing along y-axis 
3.  Simulated constant variance per dose group (σ= 0.3). 
Upper limit of x-axis has been reduced for clarity. 
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Figure 3.19 Median and Relative Bias of TOPE Estimates1 Across Designs2  
for Acute TET Experiment: Simulated Activity Scores (TOPE=2 hr)  
with Rational Function Model Fit 
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1.  2000 replicates of TOPE estimates. 
2.  Each of 30 designs is designated by the value of its 2nd time of testing along the x-axis. 
Dash-dot line marks the true TOPE (2 hr). Dotted lines mark the upper and lower 5% , 10% (A) 
and 5% (B) margins of the true TOPE. 
The limits of both axes have been adjusted for better display.  
 
 
 
 
 All of the designs tested in this case were associated with relatively high mCV 
(Figure 3.20). The minimum mCV was 15.1% and was recorded for the design t2 of 0.4 
hr (Figure 3.20B). 
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 Figure 3.20 Plots of Coefficient of Variation (mCV)1 Across 30 Designs 2
of Acute TET Experiment: Simulated Activity Scores3
(TOPE = 2 hr) with Rational Function Model Fit 
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1.  MSE for each design was computed from the mean and the variance of 2000 replicates of 
TOPE estimates. mCV = 100*sqrt(MSE) / true TOPE. 
2.  Designs are designated by their 2nd testing time along the x-axis. All designs are displayed in A 
while in B the limits of the x- and y-axes have been adjusted to better display mCV. 
3.  Simulated constant variance per dose group (σ= 0.3). 
Vertical dash-dot line passes through 2nd testing time at the true TOPE (2 hr). Dotted lines form 
grids to aid data point localization. 
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3.4 Summary of Results and Interpretations 
The results are summarized in Table 3.3 below. Each row (category) of the table 
represents one distinct setting of an experiment with respect to FOB domain and dose 
response model structure.  Thirty (31 for category C) different designs (of different t2) 
were evaluated within each setting. In the four categories where each involved 30 
designs, the t2 values tested ranged from 0.2 hr to 20 hr while for category C the range 
was 0.2 hr to 17 hr. The time window included the underlying TOPE (6.16 hr, 4.7 hr and 
2.0 hr) in every instance.  
In cases A & C where the simulated dataset share the same variance pattern with 
the original dataset, designs within a wide range of t2 (0.6-12 hr) yielded TOPE estimates 
with no more than 5% relative bias away from the true TOPEs. Similarly, in case E where 
the underlying TOPE was relatively small (2 hr), only the designs in the t2 range of 0.2 - 
3 hr were able to produce estimates lying within 5% relative bias.  
As the variance of the simulated data increased over that of the original dataset, a 
decreasing number of designs qualify as efficient. For example, in cases A and C where 
variance is comparable to that in the original dataset, the range of t2 required to estimate 
the TOPE to within 10% of bias was in each case 0.6 -17 hr and 0.2 – 14 hr respectively. 
However in case B (with about 200% increase in standard deviation over the most variant 
group in case A), a narrower range of t2 (2-5 hr) was required to achieve the same level of 
accuracy for estimating the TOPE. Case D is intermediate between A and B with respect 
to variance (about 40% increase) and qualifying designs (1.2 – 9 hr).   
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Table 3.3 Summary of Designs for the Estimation of TOPE 
 
Best Designs Designated by 
Best 2nd Time of Testing or t2 (hr) 
 
Experiment
/ Domain 
/Model 
 
Variance 
Pattern in 
Simulated 
Data 
  
 
True 
TOPE
(hr) 
Conver-
gence  
(%) 
Median 
within 
5% 
margin 
of 
TOPE 
Relative 
Bias 
=<5%   
Relative 
Bias 
=<10%   
mCV 
=<15%  
 
Lowest 
mCV 
 
A: 
 
TET/ 
Activity/ 
LE 
Different 
variance per 
dose group/ 
Random 
intercept 
 
 
6.16 
 
0.2 -20 
All 
designs 
(>95%) 
 
0.2 -20 
All 
designs 
 
0.6 - 15 
 
0.6 -17 
 
 
1 - 7 
 
2.0 
 
(11.3%) 
B: 
 
TET/ 
Activity/ 
LE 
Large constant 
variance  
 
σ = 2.0 
(~ 200% 
larger) 
 
 
6.16 
 
0.6 - 15 
(78 -
82%) 
 
0.4 -0.6 
 
none 
 
2 – 5 
 
none 
 
5.0 
 
(32.4%) 
C: 
 
DDT/ 
Neuro-
muscular/ 
TD 
Different 
variance per 
dose group/ 
Random 
intercept 
 
4.7 
 
0.2 -17 
All 
designs 
(>95%) 
 
0.2 -17 
All 
designs 
 
0.4 -12 
 
0.2 - 14 
 
 
0.8 - 4 
 
1.8  
 
(13.7%) 
D: 
 
TET/ 
Activity/ 
RF 
Constant 
variance  
 
σ = 1.0 
(~ 40% larger) 
 
 
6.16 
 
0.2 -10 
 (>80%) 
 
0.2 -8 
 
 
1.4 - 8 
 
1.2 – 9 
 
none 
 
2.5  
 
(18.4%) 
E: 
 
TET/ 
Activity/ 
RF 
Constant 
variance per 
dose group 
 
σ = 1.0 
 
 
2.0 
 
0.2 - 3.5 
 (>80%) 
 
0.2 -2.5 
 
0.2 - 3 
 
0.2 – 3. 
 
0.4 
 
0.4  
 
(15.1%) 
Legend:  LE Linear-exponential model 
  TD Toxico-diffusion model 
  RF Rational function model 
  TOPE Time of peak effects 
  mCV   Modified coefficient of variation   
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Generally the above findings suggest that for the cases considered, in order to 
produce reasonably accurate estimates of the TOPE to say within 5% of the true value, a 
design must choose a 2nd testing time not far away from the underlying TOPE. 
Furthermore they suggest that the presence of wide variability in the data may reduce the 
capability of designs for accurate estimation of the TOPE and further restricts the choice 
of t2 for effective designs to values less than the underlying TOPE. Although the models 
are different in most of the cases considered here, it is reasonable to expect that variation 
in data may influence the designs as suggested by our findings. 
With respect to mCV, the bias and variance of estimation are combined. There is 
a direct linear relationship between mCV and MSE with lower values of either indicating 
high precision of estimation for a given design. Compared to relative bias (=<5%), here a 
much narrower range of t2 was consistently required to achieve a desirable level of 
precision of estimates (mCV=< 15%) irrespective of the model or pattern of variance in 
the data. Generally where TOPE=6.16 hr, t2 should be about 2.5 hr in order to attain the 
smallest mCV which varied between 10% and 30% for the designs considered. For TOPE 
= 4.7 hr, the minimum mCV of 13.7% was achieved at t2=1.8 hr, however t2 would be in 
the range of about 1-4 hr in order to have mCV of no more than 15%. Similarly, a 
minimum mCV of 15% was obtained by only one design of t2=0.4 hr when the 
underlying TOPE was 2 hr.  
Overall, the number of designs with the greatest precision (smallest mCV) is a 
subset of designs with the highest validity (least bias) in the estimation of TOPE. In the 
cases considered in the this thesis, the most precise TOPE estimates were produced 
generally when the second testing time was situated about midway between time zero and 
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the underlying TOPE. An exception where the most precise design had its second testing 
time (5 hr) relatively closer to the underlying TOPE (6.16 hr) was category B where 
variability in the sample was large (σ=2).  Here the smallest attainable relative bias 
(about 10%) and mCV (about 32%) were comparatively larger than those of other 
categories. It should be recalled that the trends of both measures (relative bias and mCV) 
across designs were rather unstable in the minimum regions (refer to Figures 3.6 & 3.8). 
The implication is that for this category, there is probability that the appropriate t2 for the 
most effective design could be anywhere from 2 hr to 6 hr, which still leans more to the 
lower side of the underlying TOPE of 6.16 hr.  
In all, the t2 value of each of these identified effective designs remained smaller 
than the underlying TOPE. It follows that under various combinations of conditions such 
as exposure agent, neurobehavioral domain, statistical model, or value of the underlying 
TOPE, all of the qualifying effective designs seemed to share a common robust feature 
that the 2nd testing time should be chosen at a point a little earlier than the underlying 
TOPE in order to achieve robust estimation of the TOPE.  
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CHAPTER 4 
DISCUSSION 
 
The IPCS/EPA Collaborative Study protocol (Moser et al, 1997b) under which 
the existing FOB data were generated proposed that the 2nd testing in a particular 
experiment be performed at the time of peak effects (TOPE) for that chemical. The TOPE 
is derived using two endpoints through a pilot experiment. Since true TOPE may vary 
with the testing chemical, the dosing level, and the endpoint, the choice of the 2nd testing 
time can be important in determining the quality of the experiment. This thesis set out 
principally to find effective designs with respect to the choice of the second testing time 
point. Through simulation of a set of designs uniquely defined within a range of the 2nd 
testing time, the most effective designs were selected based on specified criteria.  The 
results of the study showed that many designs are robust against a misspecification of the 
TOPE choice, and can produce TOPE estimates within a relative bias of 5% margin. 
These designs are also robust with respect to the criterion mean squared error (MSE) or 
modified coefficient of variation (mCV); however the range of t2 becomes narrower 
because of the inclusion of variance in these criteria. Further, empirical evidences show 
that these designs prefer to have the 2nd testing time point before the true TOPE. 
However, it is not clear in general how earlier the second testing time point can be. 
Further investigation will be helpful before our results can be generalized to a broader 
situation.  
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The dose-response models considered in our study dictates that the TOPE is a 
function of the model parameters, and does not vary with dose level. Our simulation 
utilizes parameter values derived from several real datasets. For each design, we 
simulated 2000 replication experiments, and fit the underlying dose-response model to 
them. The convergence rate was generally high when fitting the dose-response models to 
simulated datasets.  Bias in estimating TOPE was generally negligible for most designs. 
Although, based on our findings, there seems to be reasonable latitude allowable 
around the TOPE for the choice of 2nd testing time in order for the statistical estimate of 
TOPE to be associated with no more than 5% relative bias, this may not in itself be 
sufficient or be readily achievable in practice. As our study further shows, those designs 
with second testing performed at the TOPE may be associated with relatively high MSE 
or mCV. That means that in a single experiment, there is a high probability for such 
design to yield a TOPE estimate with more than 5% deviation from the true value. 
Alternatively, designs in which the second testing were performed at about halfway 
below the true value of TOPE were credited with the least MSE in our study and 
therefore can be expected to have the highest probability of producing TOPE estimates 
within the 5% margins of the true value in a single experiment.  
The main interpretation of our findings may be exemplified as follows. Let us 
consider for example an ideal situation under the proposed IPCS/EPA protocol. Prior to a 
certain acute exposure experiment, the TOPE was accurately determined to be 4 hr post 
exposure in a range finding pilot study. As implied by the findings of this thesis, if we 
conduct the 2nd testing of the experiment  at 2 hr (or between 1 and 3 hr) post exposure, 
the subsequent statistical estimate of the TOPE has a higher probability of being close to 
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the true TOPE value of 4 hr than if we had conducted the testing at 4 hr. Therefore the 
timing of the 2nd testing has an impact on the overall capability for statistical estimation 
of the true TOPE on the basis of a fitted dose-time-response model. 
The significance of our findings can be further illustrated by exploring a scenario 
closer to real under the IPCS/EPA protocol. Major sources of uncertainty in the TOPE 
estimate obtained from a pilot study include systematic errors or bias (inaccuracy) and 
random error or statistical variation (imprecision). Therefore, if a pilot study came up 
with an estimated TOPE = 4 hr, given the uncertainty of estimation we can reasonably 
assume that the true value could be anywhere between 3 and 5 hr. If the conclusions from 
our present findings were to apply, then the 2nd testing would be performed at halfway 
below the estimated TOPE, which would be at 2 hr. In effect the 2nd testing time (2 hr) 
would be about halfway below the true TOPE (which lies anywhere between 3 and 5 hr). 
That means this design would be close to optimal in spite of the uncertainty in the TOPE 
estimate from the pilot study. On the other hand, under the IPCS/EPA protocol, the 2nd 
testing would have to be performed at 4 hr. Such design might be fairly close to optimal 
if the true TOPE was between 4 and 5 hr but the design would definitely be even further 
away from optimal if the true TOPE lied between 3 and 4 hr. 
The last scenario above is very conceivable given the fact that the pilot 
experiment based TOPE estimates obtained for just two FOB measures may not be truly 
representative of all the 30 FOB response measures both within and across 
neurobehavioral domains. Hence it is reasonable to expect that the TOPE estimate may 
be fraught with substantial uncertainty as depicted above. Designing the experiment 
proper so that the 2nd testing time is about half way below the pilot experiment based 
 57 
TOPE estimate is therefore recommendable. This may increase the probability of getting 
TOPE estimate that is close to the true value thereby facilitating effective statistical 
estimation of the TOPE. 
The findings and recommendations of this thesis may have a limited direct 
application to the OPPTS guidelines released in 1998 (US EPA, 1998b), where the 
proposed minimum times of testing are before exposure, at TOPE, and 7 and 14 days post 
exposure. The present study was evaluated under the IPCS/EPA protocol that produced 
the FOB data, and where times of testing were before exposure, at TOPE, and 1 and 7 
days post exposure. If the dosing effects are transient such that the toxic effects are 
largely washed out between day 1 and day 7, then data collected on day 14 provides very 
little additional information beyond those data collected on previous testing times. In that 
situation our findings may be inapplicable to such data generated under the 1998 
guidelines. It should be noted though that the inter-individual variability with respect to 
dose-time-response characteristic that is distributed in a given population of rats should 
be inherent to that population regardless of under which protocol (whether 1997 or 1998 
protocol) observations are made. So far as the statistical models referred to in this thesis 
adequately fit the dose-time-response trend (e.g. single peak, maximum or minimum; no 
premature washout) in a given sample, our present findings may be applicable under both 
protocols.  Nevertheless, the potential impact that the difference between data generated 
under both protocols may have on statistical modeling should be a subject of future study.  
In further research it will be useful to investigate whether at least two testing time 
points surrounding the TOPE may be needed, one earlier and one later. It will also be 
helpful to assess the impact of TOPE estimate on the variability of Benchmark dose 
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(BMD) which is related to the TOPE estimate. Such research may help to further quantify 
the relative contributions of the comparison designs tested in this thesis to the variation in 
TOPE and BMD estimations. 
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